🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 23 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 18/04/2007 | 31,68 | 31,99 | 31,15 | 31,65 | -0,09% | 2,65% | 2.363.400 |
| 17/04/2007 | 30,00 | 32,20 | 29,70 | 31,68 | +5,85% | 8,33% | 6.072.700 |
| 16/04/2007 | 28,65 | 29,93 | 28,27 | 29,93 | -0,76% | 5,79% | 8.893.500 |
| 13/04/2007 | 31,25 | 31,41 | 28,96 | 30,16 | -4,41% | 7,84% | 6.048.900 |
| 12/04/2007 | 31,24 | 32,05 | 31,02 | 31,55 | +1,71% | 3,30% | 3.259.300 |
| 11/04/2007 | 32,40 | 32,51 | 30,60 | 31,02 | -3,42% | 5,90% | 2.776.300 |
| 10/04/2007 | 31,59 | 32,48 | 31,50 | 32,12 | +1,77% | 3,10% | 3.254.400 |
| 09/04/2007 | 31,00 | 31,65 | 30,95 | 31,56 | +2,07% | 2,26% | 2.225.400 |
| 05/04/2007 | 29,90 | 31,00 | 29,84 | 30,92 | +3,58% | 3,88% | 2.156.300 |
| 04/04/2007 | 29,00 | 30,00 | 29,00 | 29,85 | +3,32% | 3,45% | 2.382.800 |
| 03/04/2007 | 28,13 | 28,96 | 28,01 | 28,89 | +3,40% | 3,38% | 1.265.300 |
| 02/04/2007 | 28,14 | 28,43 | 27,70 | 27,94 | -0,36% | 2,59% | 1.134.600 |
| 30/03/2007 | 28,16 | 28,60 | 27,81 | 28,04 | -0,28% | 2,81% | 924.700 |
| 29/03/2007 | 27,96 | 28,34 | 27,68 | 28,12 | +0,90% | 2,36% | 1.219.800 |
| 28/03/2007 | 27,64 | 28,07 | 27,55 | 27,87 | +1,01% | 1,88% | 1.739.300 |
| 27/03/2007 | 28,29 | 28,92 | 27,58 | 27,59 | -1,15% | 4,74% | 1.707.300 |
| 26/03/2007 | 28,00 | 28,19 | 27,58 | 27,91 | -0,50% | 2,18% | 848.100 |
| 23/03/2007 | 28,22 | 28,48 | 27,81 | 28,05 | -0,14% | 2,37% | 955.000 |
| 22/03/2007 | 28,57 | 28,90 | 27,99 | 28,09 | -0,95% | 3,19% | 1.761.700 |
| 21/03/2007 | 27,86 | 28,83 | 27,54 | 28,36 | +1,83% | 4,63% | 2.479.500 |
| 20/03/2007 | 27,66 | 28,02 | 27,31 | 27,85 | +0,72% | 2,57% | 1.261.100 |
| 19/03/2007 | 27,20 | 27,78 | 27,09 | 27,65 | +2,07% | 2,54% | 2.415.500 |
| 16/03/2007 | 28,09 | 28,22 | 26,98 | 27,09 | -3,83% | 4,41% | 3.011.700 |
| 15/03/2007 | 28,17 | 28,42 | 27,80 | 28,17 | +0,36% | 2,20% | 1.568.800 |
| 14/03/2007 | 28,83 | 28,89 | 27,82 | 28,07 | -3,57% | 3,71% | 3.015.500 |
| 13/03/2007 | 30,12 | 30,18 | 29,05 | 29,11 | -4,24% | 3,75% | 1.494.400 |
| 12/03/2007 | 29,92 | 30,95 | 29,69 | 30,40 | +3,79% | 4,21% | 1.845.400 |
| 09/03/2007 | 29,18 | 29,73 | 29,01 | 29,29 | +0,03% | 2,47% | 882.500 |
| 08/03/2007 | 29,88 | 29,94 | 28,95 | 29,28 | -0,78% | 3,31% | 1.794.300 |
| 07/03/2007 | 29,40 | 29,60 | 29,01 | 29,51 | +0,00% | 2,01% | 1.530.700 |